Upstream Bio, Inc. (UPB): Rasio rega marang prakiraan pendapatan
Upstream Bio Inc (UPB) is developing advanced TSLP antibodies to combat dermatitis and asthma. This chart of the company's expected P/S ratio reflects valuation dynamics, with the metric currently at 54.40. The firm is currently deploying its post-IPO capital toward costly R&D research; however, the lack of sales and reliance on debt create significant risks in the event of potential clinical trial failures.
Rincian metrik komprehensif lan analitis Upstream Pharma (UPB)
- rega saham lan target rega konsensus:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- indikator beban utang lan likuiditas:
Utang marang Ekuitas Upstream Bio Inc|UPB - Koefisien utang jangka dawa marang modal|Utang jangka cendhak marang modal Upstream Bio Inc|UPB - Utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Upstream Pharma|UPB - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Upstream Bio|Indikator likuiditas cepet upstreambio.com
- data bathi bisnis lan rasio investasi:
UPB - Bathi pungkasan|Proyeksi bathi mangsa ngarep Upstream Bio Inc|UPB - Rasio rega marang bathi|Pangali Forward P/E Upstream Bio Corp|UPB - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Upstream Pharma|UPB - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Upstream Bio|UPB - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan upstreambio.com|UPB - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Upstream Bio Inc
- indikator volume dodolan lan pendapatan:
Analisis wiwitan perusahaan:Upstream Bio UPB
The value of Upstream Bio Inc (UPB) is driven by the clinical success of verekimab and FDA approval. The estimated forward P/S ratio compares current market capitalization with expected future sales, measuring the premium for potential growth. This chart reflects the level of market optimism regarding the return on R&D expenditures. A decrease in the multiple confirms valuation resilience, whereas its growth increases risks in the event of any operational disruptions.
Pesaing Upstream Bio Inc
argenx - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S BioNTech Inc. BNTX|ABVX - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan ADMA|Protagonist Therapeutics (PTGX) - Rasio rega marang prakiraan pendapatan|IMVT - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan KNSA|GRFS (Grifols SA) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Adaptive Biotechnologies Corp (ADPT)|CLDX (Celldex Corp) - Rega forward marang dodolan|Multiplikator Forward P/S AUPH (Aurinia Pharmaceuticals)|biocryst.com (BCRX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Vera Therapeutics - Multiplikator Forward P/S|DNTH - Multiplikator Forward P/S|Pharvaris Corp (PHVS) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan AbCellera Corp|Multiplikator forward rega marang pendapatan TRML|PGEN: Rega forward marang dodolan|Multiplikator Forward P/S PHAR|Rasio rega marang prakiraan pendapatan NKTR (Nektar Therapeutics Inc)|Multiplikator Forward P/S ZBIO (Zenas Biopharma, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Immunome Bio (IMNM)|GOSS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep kalvista.com|SEPN (Septerna) - Multiplikator forward rega marang pendapatan|Pieris Pharma - Rega forward marang dodolan|SVRA (Savara Corp) - Multiplikator Forward P/S|Rigel Corp (RIGL) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan AnaptysBio, Inc. (ANAB)|astriatx.com - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S ENGN (enGene)|RAPT - Multiplikator forward rega marang pendapatan|JBIO: Multiplikator forward rega marang pendapatan|ACRS - Multiplikator Forward P/S|Kyverna Therapeutics (KYTX) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan VTYX|Rasio rega marang prakiraan pendapatan Theratechnologies Inc (THTX)|AVTX: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ELDN (Eledon Pharmaceuticals)|Rega forward marang dodolan AGEN|Climb Bio - Multiplikator Forward P/S|ZURA - Multiplikator Forward P/S|aTyr (ATYR) - Rasio rega marang prakiraan pendapatan|Adagene Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan ImageneBio|Multiplikator forward rega marang pendapatan Shattuck Therapeutics (STTK)|Multiplikator Forward P/S EQ|Multiplikator Forward P/S connectbiopharm.com (CNTB)|Immunic - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ATRA|InflaRx GmbH - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake x4pharma.com XFOR|adicetbio.com (ACET) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Celularity|Rasio rega marang prakiraan pendapatan INmune Bio Corp|Multiplikator forward rega marang pendapatan Barinthus Biotherapeutics Corp (BRNS)|Multiplikator forward rega marang pendapatan KZR (Kezar Life Sciences)|Multiplikator Forward P/S sabbiotherapeutics.com (SABS)|Rasio rega marang prakiraan pendapatan Akari Therapeutics Plc AKTX|ENLV: Kapitalisasi marang prakiraan pendapatan|Q32 Bio Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GeoVax Corp|EDSA (Edesa Biotech, Inc.) - Multiplikator forward rega marang pendapatan|ibioinc.com (IBIO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Carisma Therapeutics Inc|XTL Biopharmaceuticals Ltd - Rega mangsa ngarep marang pendapatan|Rasio rega marang prakiraan pendapatan Bolt Biotherapeutics (BOLT)|Rasio kapitalisasi marang dodolan sing dikarepake hcwbiologics.com|Aptevo Therapeutics Inc. - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake AIM (AIM ImmunoTech, Inc.)|ADTX - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan GRI (GRI Bio Inc)|XRTX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Vyome Therapeutics (HIND)|REVB (Revelation Biosciences) - Multiplikator Forward P/S|Multiplikator Forward P/S indaptusrx.com|Rasio rega marang prakiraan pendapatan Scinai Immunotherapeutics Ltd. (SCNI)|Multiplikator forward rega marang pendapatan calcimedica.com CALI|Affimed N.V. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ALLK|HOOKIPA - Multiplikator Forward P/S|IGMS: Rasio rega marang prakiraan pendapatan|ITOS: Multiplikator Forward P/S|OCEA - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan TC BioPharm (Holdings) PLC|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Third Harmonic Bio Inc THRD
